The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
18 years of age or older.
Participant must reside in Ontario, Canada.
Ability to speak and read English (participant to provide written informed consent and participate in PEARL intervention, as determined by study personnel).
No cognitive impairment indicated in medical record or by the primary care physician.
A history of past intolerability to psilocybin or other psychedelics.
Past/present psychiatric diagnoses of bipolar disorder, any psychotic disorder, active substance use disorders, or dementia.
Clinically significant suicidal ideation either currently or within the past 6 months, as judged by study clinicians.
Participant under the age of 30 years who has a first degree relative with a primary psychotic disorder.